INFOGRAPHICS

Explore our summarised infographics.

Prescribing information for DOVATO (dolutegravir/lamivudine) can be found here.
Prescribing information for VOCABRIA (cabotegravir) + REKAMBYS (rilpivirine) can be found here.

Results:

Showing results for

VOCABRIA + REKAMBYS

Key data evaluating the efficacy, safety, and tolerability of switching virologically supressed (HIV-1 RNA ,50 copies/mL) adults to every 2-months Vocabria + Rekambys – versus continuing maintenance therapy with oral standard of care - in a sub-Saharan African population. The study was managed using a public health approach with viral load testing every 24 weeks.

DOVATO

5 Years of Clinical and Real World Evidence Data

DOVATO

Data from the DYAD and SOUND study from ID Week 2023

DOVATO

24 week data from the D2ARLING study from IAS 2023

DOVATO

Head to Head data from RUMBA with DTG/3TC vs BIC/F

DOVATO

Some key data from IDWeek & Glasgow 2022

VOCABRIA + REKAMBYS

Key SOLAR PRO data

AIDS

Some key data from AIDS 2022

PM-GB-HVX-WCNT-220003 | March 2024

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.